€2.7 Million: IntelliProve Bets Humanoid Robots Can Read Vital Signs Through Their Cameras

Belgian startup IntelliProve raised a €2.7 million seed round to extend its camera-based vital sign technology from virtual care into humanoid robots used in elder care.

Key Takeaways

  • IntelliProve raised a €2.7 million seed round on November 19, 2026, led by Miles Ahead, to extend its camera-based vital sign technology into humanoid robots.
  • The technology uses remote photoplethysmography to measure six biomarkers, including heart rate and blood pressure, from a 30-second camera scan with no physical contact.
  • IntelliProve's core virtual care platform already operates in more than 50 countries and has been validated on over 6 million data points.
  • The company supplies a software layer rather than building robots itself, aiming to let any camera-equipped humanoid monitor residents' health passively in elder care settings.

€2.7 Million: IntelliProve Bets Humanoid Robots Can Read Vital Signs Through Their Cameras

IntelliProve, a Belgian health-sensing startup, closed a €2.7 million seed round on November 19, 2026, led by Miles Ahead with participation from Wit-Gele Kruis, imec.istart and several business angels. The company's technology turns any ordinary camera — including the ones already mounted on humanoid robots — into a contactless vital signs monitor, according to Robotics 24/7.

Founded by Joeri Tulkens and Tanguy Sanglet, IntelliProve uses remote photoplethysmography, a technique that detects tiny color changes in skin caused by blood flow, to extract six biomarkers from a 30-second camera scan: heart rate, heart rate variability, respiratory rate, systolic and diastolic blood pressure, and resonant breathing. The company has already validated its proprietary VitalMesh, TripleGate and PulseShape algorithms on more than 6 million data points and holds ISO 27001 certification, and its virtual care platform already operates in more than 50 countries.

Why Robots Need a Health Sensing Layer

Humanoid and companion robots deployed in elder care settings face an obvious limitation: they can see a resident but, without dedicated medical hardware, cannot tell whether that person is in distress. IntelliProve's pitch is that it closes that gap without adding sensors, wearables or physical contact — the robot's existing camera becomes a passive health monitor running in the background of whatever task it is already doing. The company frames this as giving robots \"extra context about a resident,\" which matters for fall risk assessment, routine wellness checks and early detection of cardiovascular changes in settings where staff cannot continuously monitor every patient.

This slots into a broader trend of companion and service robots moving from novelty demonstrations toward verifiable utility in healthcare and elder care — a sector where companies like Andromeda Robotics and Ottobock-adjacent exosuit makers are also chasing deployment, but largely through movement assistance or social interaction rather than passive vital-sign capture. IntelliProve's approach is narrower and more clinical: it does not build robots at all, instead supplying a software layer that any robot or camera-equipped device maker can license.

A Crowded Field for Camera-Based Vitals

Contactless vital sign monitoring is not new — companies such as Binah.ai and Nuralogix have pursued similar rPPG-based approaches for years, mostly aimed at telehealth and insurance screening rather than robotics specifically. IntelliProve's academic partnerships with TU Delft and Ghent University Hospital, plus its existing footprint across more than 50 countries of virtual care deployments, give it a validation base competitors targeting robotics from a cold start would lack.

The trade-off is accuracy versus convenience. Camera-based vital sign estimation is inherently noisier than contact sensors like pulse oximeters or blood pressure cuffs, particularly under variable lighting or when a subject is moving — conditions a mobile robot's camera will encounter far more often than a stationary telehealth kiosk. IntelliProve has not disclosed clinical-grade accuracy figures specific to robotic deployment, and its robotics partners remain unnamed. Whether health systems trust robot-derived vitals enough to act on them, rather than treating them as a screening flag for human follow-up, will determine how far this €2.7 million round actually travels beyond pilot programs.

Category: Hospital Automation

Tags: humanoid robots Elder Care hospital automation IntelliProve Health Sensing rPPG

Related Articles

Frequently Asked Questions

What does IntelliProve's technology do?

It turns any camera into a contactless vital-sign monitor using remote photoplethysmography, measuring heart rate, heart rate variability, respiratory rate, blood pressure and breathing from a 30-second scan.

How much funding did IntelliProve raise?

IntelliProve raised a €2.7 million seed round on November 19, 2026, led by Miles Ahead with participation from Wit-Gele Kruis and imec.istart.

How does this apply to humanoid robots?

Robots equipped with cameras can use IntelliProve's software to passively assess a resident's vital signs in elder care settings without additional hardware.

Who founded IntelliProve?

IntelliProve was founded by Joeri Tulkens and Tanguy Sanglet and is based in Belgium.